Dr. Robert Schier is a Senior Investment Director at Zürcher Kantonalbank Asset Management (Swisscanto Private Equity).
In 2018, Robert joined Zürcher Kantonalbank as an Investment Director in the Private Markets team. He has many years of experience in the healthcare and life sciences sector. After completing his doctorate, he held various positions in biotech and venture capital companies, and in 2009, he set up his own consultancy firm.
Since 2001, Robert has worked as an investment director and/or partner in various funds. Overall, he has been in charge of investments in more than 20 different private start-ups, as well as another 25 companies as part of an investment committee. In addition, he was appointed to the Board of Directors of around 25 life sciences companies.
Robert holds a degree in pharmacy from the University of Vienna and a Ph.D. in biotechnology from the University of Natural Resources and Life Sciences, Vienna. He received the Keystone Award for Excellence in Research for his outstanding doctoral thesis, which he completed at the University of California, San Francisco. Robert obtained an executive MBA from the European University and is the author of several scientific publications and patents.